Angiogenesis inhibitors in the treatment of prostate cancer
about
Progress of molecular targeted therapies for prostate cancersEndothelial Caveolin-1 regulates the radiation response of epithelial prostate tumors.Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.Targeted therapy in prostate cancer.Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy.Antiangiogenic therapy for cancer: an updateVasculogenic Mimicry in Prostate Cancer: The Roles of EphA2 and PI3K.A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.Severity of hematuria effects resolution in patients treated with hyperbaric oxygen therapy for radiation-induced hematuria.Aberrant BAF57 signaling facilitates prometastatic phenotypes.Nanoparticles as new tools for inhibition of cancer angiogenesis.Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.Vascular endothelial growth factor (VEGF) expression and microvascular density in salivary gland tumours.Emerging treatments for castrate-resistant prostate cancer.Anti-angiogenic therapies in prostate cancer
P2860
Q26823014-936B3E6B-1EDA-4631-818D-FB386F4847E0Q30652492-990D7660-5571-4817-AC0D-01865F395E8FQ34450860-4AB20238-186C-47C3-BBEB-A25B2A6C8F62Q34634763-553458F2-F21A-4E1E-BC74-3F16B6750821Q34984769-E069CF4F-B6DC-48AE-B115-3AE4D85B9395Q36563542-48E0F50E-24E0-4AAE-B165-563D909793DEQ37015731-79C70827-ECE1-41C8-BCD9-E76F8B81C6AFQ37258981-FC02B93F-4776-4300-A81C-BE61ED4AF7EBQ37580399-E48B6DD1-26EE-4F88-9363-E4591CE78DA2Q38126979-CB93BC55-5CFF-4E13-9AD8-0A1825ADE248Q38317088-08B342E2-E7FC-4E3B-AC07-35068BF00ED1Q39329359-5BE652AC-2BD4-4F49-B16D-A4A9030CCA93Q39340234-478DBCA0-6A3F-431F-A50E-85229445C479Q42443003-0E7D7FAB-DC97-4E14-A97D-125307F17A34Q44336766-63AC4D7E-EA76-419D-83AE-09501E72A57EQ57132472-ACAC5AB3-B3C7-433F-BF7A-AA219F83699D
P2860
Angiogenesis inhibitors in the treatment of prostate cancer
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2010
@uk
name
Angiogenesis inhibitors in the treatment of prostate cancer
@en
Angiogenesis inhibitors in the treatment of prostate cancer
@nl
type
label
Angiogenesis inhibitors in the treatment of prostate cancer
@en
Angiogenesis inhibitors in the treatment of prostate cancer
@nl
prefLabel
Angiogenesis inhibitors in the treatment of prostate cancer
@en
Angiogenesis inhibitors in the treatment of prostate cancer
@nl
P2860
P356
P1476
Angiogenesis inhibitors in the treatment of prostate cancer
@en
P2093
Clara Hwang
Elisabeth I Heath
P2860
P2888
P356
10.1186/1756-8722-3-26
P407
P5008
P577
2010-08-02T00:00:00Z
P6179
1011249701